The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antidepressant of No Clear Value in Chronic Low-Back Pain

Antidepressant of No Clear Value in Chronic Low-Back Pain

October 4, 2018 • By Will Boggs MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Low-dose amitriptyline does not have clear benefits for patients with chronic low-back pain that has no specific cause, according to results from a randomized clinical trial.

You Might Also Like
  • Mind-Body Therapy Helps Ease Chronic Low Back Pain
  • NKTR-181 Promising for Chronic Low Back Pain
  • Being Active May Reduce Risk of Chronic Low Back Pain
Also By This Author
  • Upadacitinib Monotherapy Effective in Refractory Rheumatoid Arthritis

Despite the lack of evidence that antidepressants are more effective than placebo for low-back pain, seven of 14 national and international guidelines recommend their use in this setting.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Donna M. Urquhart from Monash University in Melbourne, Australia, and colleagues investigated whether low-dose amitriptyline (25 mg per day) is effective in reducing pain, disability and work absence and hindrance over six months in 146 patients with chronic, nonspecific low-back pain, compared with benztropine, which mimics the adverse events of amitriptyline but has no known effect on chronic pain.

At baseline, participants had a mean pain score of 41.6/100 and a mean disability score of 7.9/23. A quarter of patients reported work absence and 85% reported hindrance owing to low-back pain, the researchers report in JAMA Internal Medicine, online October 1.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pain intensity declined by a mean 12.6 points in the amitriptyline group and by a mean 4.8 points in the benztropine group at six months. Both differences were well below the minimal clinically important difference (MCID) of 15 points, and the difference between the groups was not statistically significant.

Disability scores improved to a significantly greater extent in the amitriptyline group at three months, but the three-point improvement barely achieved the MCID, and improvements at six months did not differ between the groups.

At six months, the groups did not differ significantly in work absence, hindrance, global improvement, depression, general health, or fear of movement/reinjury.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“The most interesting result is that we found that low-dose amitriptyline tended to reduce back-related disability and pain intensity, suggesting it may be an effective treatment option for back pain,” Dr. Urquhart told Reuters Health by email.

“This is particularly important given effective treatments for back pain are limited and recent studies have shown that medications, such as paracetamol (acetaminophen), anti-inflammatories, and narcotics, don’t work,” she said.

“The cornerstone of back pain management is for patients to stay active,” Dr. Urquhart said. “However, where a patient and their doctor decide they need extra support for a short to medium period, low-dose amitriptyline may be worth considering.”

She added, “We found that prior to the commencement of the study more than 30% of participants in each group had moderate to severe symptoms that were similar to the side effects associated with low-dose amitriptyline. Given these symptoms were not a result of the study medication, they suggest that a significant proportion of the symptoms patients with low back pain report are not related to their medication use. This is important for physicians to take into consideration when they are assessing side effects thought to relate to low-dose amitriptyline.”

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: amitriptyline, antidepressants, chronic low-back pain

You Might Also Like:
  • Mind-Body Therapy Helps Ease Chronic Low Back Pain
  • NKTR-181 Promising for Chronic Low Back Pain
  • Being Active May Reduce Risk of Chronic Low Back Pain
  • Don’t Reach for Pills for Most Chronic Low Back Pain

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.